Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 2, 2012, Pages 474-480

  Ha, Sang Jin ^a   Kim, Weon ^a   Woo, Jong Shin ^a   Kim, Jin Bae ^a   Kim, Soo Joong ^a   Kim, Woo Shik ^a   Kim, Myeong Kon ^a   Cheng, Xian Wu ^b   Kim, Kwon Sam ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

endothelium; ischemia; pharmacology; reperfusion injury

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; EXENDIN 4; GLIBENCLAMIDE; GLYCERYL TRINITRATE; PLACEBO;

ADULT; ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY ENDOTHELIUM; ARTICLE; BRACHIAL ARTERY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED DILATATION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; VASODILATATION;

ADULT; BRACHIAL ARTERY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FOREARM; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; KATP CHANNELS; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; REPERFUSION INJURY; VASODILATION; VENOMS;

EID: 84862795550     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.222653     Document Type: Article

References (46)

1. Laude K, Beauchamp P, Thuillez C, Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55:466-473.
2. Mankad PS, Amrani M, Rothery S, Severs NJ, Yacoub MH. Relative susceptibility of endothelium and myocardial cells to ischaemiareperfusion injury. Acta Physiol Scand. 1997;161:103-112.
3. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation. 2001;103: 1624-1630.
4. Bayerle-Eder M, Wolzt M, Polska E, Langenberger H, Pleiner J, Teherani D, Rainer G, Polak K, Eichler HG, Schmetterer L. Hypercapnia-induced cerebral and ocular vasodilation is not altered by glibenclamide in humans. Am J Physiol. 2000;278:R1667-R1673.
5. Beresewicz A, Maczewski M, Duda M. Effect of classic preconditioning and diazoxide on endothelial function and O2-and NO generation in the post-ischemic guinea-pig heart. Cardiovasc Res. 2004;63:118-129.
6. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005:15;111:742-746.
7. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem. 1993;268:19650-19655.
8. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219-224.
9. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res. 2001;89:445-452.
10. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-151.
11. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardio. 2009;53:501-510.
12. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol. 1990;16:349-356.
13. Lee BK. Computational fluid dynamics in cardiovascular disease. Korean Circ J. 2011;41:423-430.
14. Sinoway LI, Hendrickson C, Davidson WRJ, Prophet S, Zelis R. Characteristics of flow-mediated brachial artery vasodilation in human subjects. Circ Res. 1989;64:32-42.
15. Smiesko V, Kozik J, Dolezel S. Role of endothelium in the control of arterial diameter by blood flow. Blood Vessels. 1985;22:247-251.
16. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension. 1986;8: 38-44.
17. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-1115.
18. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994;74: 64-65.
19. Li YJ, Rha SW, Chen KY, Jin Z, Minami Y, Wang L, Dang Q, Poddar KL, Ramasamy S, Park JY, Oh DJ, Jeong MH; Korea Acute Myocardial Infarction Registry Investigators. Clinical characteristics and mid-term outcomes of acute myocardial infarction patients with prior cerebrovascular disease in an Asian population: lessons from the Korea Acute Myocardial Infarction Registry. Clin Exp Pharmacol Physiol. 2010;37: 581-586.
20. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J. 2010;31:2854-2861.
21. Liuni A, Luca MC, Lisi M, Dragoni S, di Stolfo G, Mariani JA, Uxa A, Gori T, Parker JD. Observations of time-based measures of flowmediated dilation of forearm conduit arteries: implications for the accurate assessment of endothelial function. Am J Physiol Heart Circ Physiol. 2010;299:H939-H945.
22. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Rand WM, Udelson JE, Karas RH. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol. 2001;38: 1843-1849.
23. Chen SM, Tsai TH, Hang CL, Yip HK, Fang CY, Wu CJ, Guo GB. Endothelial dysfunction in young patients with acute ST-elevation myocardial infarction. Heart Vessels. 2011;26:2-9.
24. Kaeffer N, Richard V, François A, Lallemand F, Henry JP, Thuillez C. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol. 1996;271:H842-H849.
25. Pearson PJ, Schaff HV, Vanhoutte PM. Long-term impairment of endothelium-dependent relaxations to aggregating platelets after reperfusion injury in canine coronary arteries. Circulation. 1990;81:1921-1927.
26. Chu A, Chambers DE, Lin CC, Kuehl WD, Palmer RM, Moncada S, Cobb FR. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs. J Clin Invest. 1991;87:1964-1968.
27. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639-646.
28. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
29. Tomai F, Crea F, Chiariello L, Gioffrè PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation. 1999; 100:559-563.
30. O'Rourke B. Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res. 2004;94:420-432.
31. Katnik C, Adams DJ. An ATP-sensitive potassium conductance in rabbit arterial endothelial cells. J Physiol. 1995;485:595-606.
32. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol. 2001;33: 1897-1918.
33. Oldenburg O, Qin Q, Krieg T, Yang XM, Philipp S, Critz SD, Cohen MV, Downey JM. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol. 2004;286:H468-H476.
34. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation. 2001;103:2935-2941.
35. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A, Chiariello L, Gioffrè PA. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K channel blocker. Circulation. 1994;90:700-705.
36. Downey JM, Cohen MV. Mechanisms of preconditioning: correlates and epiphenomena. In: Marber MS, Yellon DM, eds. Ischemia: Preconditioning and Adaptation. Oxford, UK: BIOS Scientific Publishers Limited; 1996:21-34.
37. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243-249.
38. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation. 2008;117: 2340-2350.
39. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59: 1030-1037.
40. Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1(9-36) amidemediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology. 2010;151:1520-1531.
41. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125:173-177.
42. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215.
43. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23:334-339.
44. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-E1295.
45. Nugent AG, McCurk C, McAuley d, Maguire S, Silke B, Johnston GD. Forearm reactive hyperaemia is not mediated by nitric oxide in healthy volunteers. Br J Clin Pharmacol. 1999;48:457-459.
46. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88: 3082-3089.